Back to results
US 10,493,064 B2Granted
IBS microbiota and uses thereof
AssigneeSalix Pharmaceuticals, Inc.
InventorsPam Golden, Anthony Fodor, Enoch Bortey, William Forbes
Life of this patent
Estimating the term…
Abstract
The instant application provides methods of diagnosing and treating a subject having IBS. In certain embodiments, the methods also include diagnosing subjects who will respond to IBS treatment with rifaximin.
Claims4
A method of diagnosing and treating a subject having IBS, comprising:
- determining that the subject will respond to rifaximin by
- sequencing the V4 hyper-variable region of the 16S rRNA gene of bacteria obtained from a fecal sample of the subject;
- and
- assigning a number of operational taxonomic units (“OTUs”) based on the V4 hyper-variable region of the 16S rRNA gene sequence to one or more taxa selected from Sphingobacteriaceae, Phyllobacteriaceae, Flavobacteriaceae, Sutterellaceae, Thermoanerobacteraceae, and Burkholderialesincertae sedis,
- wherein an OTU includes a cluster of sequences that have at least 97% identity;
- and
- wherein the subject will respond to rifaximin treatment if the number of OTUs is selected from the group consisting of the OTU of Sphingobacteriaceae greater than 2.056, the OTU of Phyllobacteriaceae greater than 0.540, and the OTU of Flavobacteriaceae greater than 2.928, the OTU of Sutterellaceae less than 3.96, the OTU of Thermoanaerobacteraceae less than 0.253, the OTU of Burkholderialesincertae sedis less than 0.259, and any combination thereof before the rifaximin treatment;
- and
- administering an effective amount of rifaximin to the subject who will respond to rifaximin treatment.
6 more elements
Dependencies are inferred from the claim text.